ASCO 2022 Lung cancer (腫瘤科年會-肺癌部分）

四期肺癌：
1. A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.
From Dr. Felip in spain. 
--Conclusion: E + P is safe and shows encouraging antitumor activity. 最近TIGI的數據不太好。希望這個LAG3 protein 有戲，二期臨床數據好，也不能高興得太早。

2. Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2.
--不需要exon-20 insertion. ORR 29%. 主要是亞洲病人

3. KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
Mirati Therapeutics的Kras inhibitor, ORR 42.9%. Amgen sotorasib估計有競爭了，還在等三期臨床

4. Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A.
--conclusion: Pembrolizumab + ramucirumab in pts with advanced NSCLC previously treated with chemotherapy and immunotherapy led to improved OS compared to SOC。現在沒有在front-line exposed to IO的病人不多了 （除去EGFR/ALK mutated). 

5. SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).
--Negative result by news press release

6. Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis.
--conclusion: Patients with KRAS-mutated NSCLC derived the greatest benefit from the combination of chemo-ICI as compared to ICI or chemo alone, benefit from 1L chemo-ICI similarly to those with KRAS wild-type NSCLC, and should receive combination therapy upfront. No surprise to me. 

7. Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis.
--most subgroups of patients with advanced NSCLC with PD-L1 score ≥50% receiving FDA-approved chemo-IO regimens may have OS and PFS outcomes that are comparable with or better than IO-only regimens. Patients ≥75 years of age receiving chemo-IO may not have improved outcomes over IO.

8. Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.
--promising result, waiting for phase III study. I am not a big fan of Cabo, not well tolerated. 

9. Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study.
--Shanghai Henlius Biotech， positive study, OS 15.4 vs.10.9 months (15個月很厲害！），不知道會不會在美國得到批準。

早期肺癌：
1. Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial.
Neoadjuvant chemoIO就是不錯，pCR 36.2%, 這個trial 還要有EFS才行。
還有一個small cell lung, chemoXRT, bid XRT的， 還是daily XRT似乎更方便一些。
另外兩個neoadjuvant chemoIO study, 不疼不癢，就不記錄了。